Drugs / MPLA-L
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT04844775 Background | Aug 2022 → Sep 2024 | — | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 2 | NCT04066881 Background | Dec 2020 → Dec 2024 | HIV infectious disease | MRC/UVRI and LSHTM Uganda Research Unit | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MPLA-L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04066881 ↗ |
| Modality | Other / unclassified | “MPLA is a non-toxic version of LipoPolySaccharide (LPS)” NCT04844775 ↗ |
| Route | Intramuscular | “0.4mL containing a mixture of 100mcg CN54gp140 and 5mcg MPLA-L will be injected into the deltoid muscle of the right upper arm” NCT04066881 ↗ |